Marshall Wace, LLP Tenaya Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 17,285 shares of TNYA stock, worth $23,507. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,285
Previous 148,089
88.33%
Holding current value
$23,507
Previous $90,000
71.11%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding TNYA
# of Institutions
98Shares Held
38.2MCall Options Held
313KPut Options Held
61.1K-
Column Group LLC San Francisco, CA9.4MShares$12.8 Million18.17% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$6.89 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.5MShares$6.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$5.54 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.68MShares$2.28 Million0.0% of portfolio
About Tenaya Therapeutics, Inc.
- Ticker TNYA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,364,700
- Market Cap $56.3M
- Description
- Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...